20 March 2026
20 March 2026
The trial will examine the efficacy, safety, and pharmacodynamics of S-606001 SRT used with ERT in confirmed LOPD adults.
The acquisition brings in the Aidaptus auto-injector platform and related intellectual property.
The investment will fund the Phase I/Ib study of CGX-926 for MC4R-deficient genetic obesity in healthy subjects and patients.
The MC2 system enables examinations in the same room as caregivers, reducing the need to separate families during procedures.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
